Maturitas
Volume 55, Issue 2 , Pages 162-173 , 20 September 2006

Results from the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]

  • Piret Veerus

      Affiliations

    • Department of Epidemiology and Biostatistics, National Institute for Health Development (TAI), Tallinn, Estonia
    • Estonian Center of Excellence in Behavioral and Health Sciences, Tallinn, Estonia
    • Tampere School of Public Health, University of Tampere, Tampere, Finland
    • Corresponding Author InformationCorresponding author. Tel.: +372 6 593 941; fax: +372 6 593 901.
    • ,
  • Sirpa-Liisa Hovi

      Affiliations

    • Department of Health and Social Services, National Research and Development Centre for Welfare and Health (STAKES), Helsinki, Finland
    • Tampere School of Public Health, University of Tampere, Tampere, Finland
    • ,
  • Krista Fischer

      Affiliations

    • Department of Public Health, University of Tartu, Tartu, Estonia
    • ,
  • Mati Rahu

      Affiliations

    • Department of Epidemiology and Biostatistics, National Institute for Health Development (TAI), Tallinn, Estonia
    • Estonian Center of Excellence in Behavioral and Health Sciences, Tallinn, Estonia
    • ,
  • Matti Hakama

      Affiliations

    • Tampere School of Public Health, University of Tampere, Tampere, Finland
    • ,
  • Elina Hemminki

      Affiliations

    • Estonian Center of Excellence in Behavioral and Health Sciences, Tallinn, Estonia

Received 3 October 2005 ,Revised 26 January 2006 ,Accepted 30 January 2006.

References 

  1. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605–613
  2. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study follow up (HERS II). JAMA. 2002;288:49–57
  3. The ESPRIT Team . Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet. 2002;360:2001–2008
  4. Clarke SC, Kelleher J, Lloyd-Jones H, Slack M, Schofield PM. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT Atherosclerosis Study. Br J Obstet Gynaecol. 2002;109:1056–1062
  5. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary–artery atherosclerosis. N Engl J Med. 2000;343:522–529
  6. Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women. A randomized controlled trial. JAMA. 2002;288:2432–2440
  7. Hodis HN, Mack WJ, Azen SP, et al. Hormone therapy and the progression of coronary–artery atherosclerosis in postmenopausal women. N Engl J Med. 2003;349:535–545
  8. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med. 2001;345:1243–1249
  9. Hoibraaten E, Qvigstad E, Arnesen H, Larsen S, Wickstrom E, Sandset PM. Increased risk of recurrent venous thromboembolism during hormone replacement therapy: results of the randomised, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost. 2000;84:961–967
  10. Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and estrogen/progestin replacement study follow-up (HERS II). JAMA. 2002;288:58–66
  11. Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease: the heart and estrogen/progestin replacement study. Ann Intern Med. 2000;132:689–696
  12. Kanaya AM, Herrington D, Vittinghoff E, et al. Glycemic effects of postmenopausal hormone therapy: the heart and estrogen/progestin replacement study: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2003;138:1–9
  13. Writing Group for the Women's Health Initiative Investigators . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321–333
  14. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349:523–534
  15. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effects of estrogen plus progestin on stroke in postmenopausal women. The Women's Health Initiative: a randomized trial. JAMA. 2003;289:2673–2684
  16. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. The Women's Health Initiative randomized trial. JAMA. 2003;289:3243–3253
  17. Shumaker S, Legault C, Rapp S, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289:2651–2662
  18. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density. The Women's Health Initiative Randomized Trial. JAMA. 2003;290:1729–1738
  19. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med. 2004;350:991–1004
  20. Hsia J, Criqui MH, Rodabough RJ, et al. Estrogen plus progestin and the risk of peripheral arterial disease. The Women's Health Initiative. Circulation. 2004;109:620–626
  21. McDonough P. The randomized world is not without its imperfections: reflections on the Women's Health Initiative Study. Fertil Steril. 2002;78:951–956
  22. MacLennan A, Sturdee D. The end of WISDOM. Climacteric. 2002;5:313–316
  23. Hemminki E, Hovi SL, Veerus P, Tuimala R, Rahu M, Hakama M. Impact of blinding on recruitment—The Estonian Postmenopausal Hormone Therapy Trial. J Clin Epidemiol. 2004;57:1237–1243
  24. Vickers M, Meade T, Darbyshire J. WISDOM: history and early demise—was it inevitable?. Climacteric. 2002;5:317–325
  25. International Statistical Classification of Diseases and Related Health Problems, 1989 Revision. Geneva: World Health Organization; 1992.
  26. Million Women Study Collaborators . Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362:419–427
  27. Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women. The Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289:2663–2672
  28. Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med. 2003;348:1839–1854
  29. Anderson GL, Judd HL, Kaunitz AM, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures. The Women's Health Initiative randomized trial. JAMA. 2003;290:1739–1748
  30. Lang K, Mägi M, Aareleid T. Study of completeness of registration at the Estonian cancer registry. Eur J Cancer Prev. 2003;12:153–156
  31. Estonian Health Insurance Fund. Available at: http://www.haigekassa.ee/HK/in_english.htm. Accessed October 14, 2004.
  32. The R Project for Statistical Computing. Available at: http://www.r-project.org. Accessed August 9, 2005.
  33. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JP. Postmenopausal hormone replacement therapy. Scientific review. JAMA. 2002;288:872–881
  34. Torgerson DJ, Bell-Seyer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA. 2001;285:2891–2897
  35. Writing Group for the PEPI Trial . Effects of hormone therapy on bone mineral density: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA. 1996;275:1389–1396
  36. Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med. 1999;106:574–582
  37. Hovi SL, Karttunen T, Karro H, Hemminki E. Comparison of Estonian and Finnish physicians’ opinions of menopause and hormone therapy. Maturitas. 2004;49:107–113
  38. Williams JG, Cheung WY, Cohen DR, Hutchings HA, Longo MF, Russell IT. Can randomised trials rely on existing electronic data? A feasibility study to explore the value of routine data in health technology assessment. Health Technol Assess. 2003;7:1–117
  39. Thorp JM, Gavin NI, Ohsfeldt RL. Hormone replacement therapy in postmenopausal women: utilization of health care resources by new users. Am J Obstet Gynecol. 2001;185:318–326
  40. Vorobjov S, Hovi S-L, Veerus P, Pisarev H, Rahu M, Hemminki E. Treatment adherence in the Estonian postmenopausal hormone therapy (EPHT) trial [ISRCTN35338757]. Maturitas. 2005;52:286–295

PII: S0378-5122(06)00058-2

doi: 10.1016/j.maturitas.2006.01.012

Maturitas
Volume 55, Issue 2 , Pages 162-173 , 20 September 2006

Article Tools

* Image Usage & Resolution